Cargando…
Adding ezetimibe to statin therapy: latest evidence and clinical implications
BACKGROUND: Statins are the hypolipemic treatment of choice for hyperlipidemia with confirmed atherosclerotic cardiovascular disease (ASCVD) protective effect, proven even in normolipemic patients. But in rare situations, even with a high-dose treatment regimen, or maximally tolerated statin dose tr...
Autores principales: | Vavlukis, Marija, Vavlukis, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044319/ https://www.ncbi.nlm.nih.gov/pubmed/30023003 http://dx.doi.org/10.7573/dic.212534 |
Ejemplares similares
-
Paraoxonase 1 gene polymorphisms in lipid oxidation and atherosclerosis development
por: Vavlukis, Marija, et al.
Publicado: (2022) -
Are diabetes mellitus and lipoprotein(a) independently or causally associated with an increased cardiovascular risk?
por: Vavlukis, Marija
Publicado: (2017) -
Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008) -
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
por: Hamilton-Craig, Ian, et al.
Publicado: (2010) -
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)